Market research
2Q3.F 9 Meters Biopharma, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 4.9
- Dividend yield
- 0.0%
- Beta
- 0.54
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US6544051096
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 4.9
- Dividend yield
- 0.0%
- Beta
- 0.54
About
About 9 Meters Biopharma, Inc
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 2Q3.F discussion.
5 years, 5 months ago
9 Meters Biopharma, Inc is currently in a long term downtrend where the price is trading 1.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
9 Meters Biopharma, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 44.3% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 99.0% to $-6M since the same quarter in the previous year.
Based on the above factors, 9 Meters Biopharma, Inc gets an overall score of 2/5.